Accelerating Viral Vectors Commercialisation to Market through Suspension Platform with Greater Predictability

[WEBINAR] Accelerating Viral Vector Commercialisation through a Suspension Platform with Greater Predictability

Exploring the next generation of non-viral gene-editing technologies, in partnership with WuXi Advanced Therapies

Developing innovative advanced therapies is one of our greatest opportunities to dramatically improve patients’ lives. In this webinar, WuXi discusses its recent technical advancement on efficient viral vector manufacturing process development. From cell line development, suspension culture of HEK293 cells, transfection, to cell culture optimisation and purification process development, a series of progress were implemented, reaching high viral titre with greater robustness, scalability and predictability. The new platforms allow WuXi to move clients with plasmids from feasibility through GMP manufacturing efficiently, e.g. AAV and lenti. 

  • how to achieve greater scalability, reproducibility and predictability
  • developing an efficient process with a high titre, yield and quality
  • AAV vector suspension platform with fully integrated in-process and release testing

register for Phacilitate webinar

Date: on demand
How: register here

Juan Lagos, Head of Upstream Process Development group, WuXi Advanced Therapies
Juan Lagos
, Head of Upstream Process Development Group, WuXi Advanced Therapies

Juan Lagos is an Associate Director of Upstream Process Development in Process and Technology Development department at WuXi Advanced Therapies. Juan has 18 years of industry experience in cell culture and upstream process development from cell line development to commercialization, covering clone selection, media development, fed-batch and perfusion process optimization, scale-up, characterisation and harvest, of IgG, IgM, fusion proteins and viral vectors. Prior to joining WuXi, Juan has worked at Pathon, a subsidiary of Thermo Fisher, BMS and Schering Plough (Merck). Juan is presently working towards his PhD in Biochemical Engineering at Rutgers University College of Engineering. He holds a B.S. in both Biochemical Engineering and Computer Science from Rutgers University.

Matthew Weaver, Head of the Downstream Process Development group, WuXi Advanced Therapies
Matthew Weaver, Head of the Downstream Process Development Group

Matt Weaver has more than 10 years’ experience in analytics, upstream and downstream process development in viral vectors and vaccines. He currently works at WuXi AppTec as head of downstream process development for cell therapies and viral vectors.


Phacilitate webinar register here